Implanet received FDA 510(k) clearance and CE Mark approval for the Jazz Claw®, a hybrid implant designed to treat degenerative spinal pathologies.
Johnson & Johnson/JNJ's business review day on May 18 filled some gaps in my understanding of the restructuring picture, but some holes remain. Here is what we learned, and what we don't know yet.
Results from a 421-patient study revealed a 97.75% survival rate at 5 years for Medacta’s AMIStem hip implant. AMIStem has been implanted >100,000 times, to date.
Medtronic commenced U.S. launch of Spine Essentials™, implants and instruments designed to lend efficiency to the most common cervical fusion procedures.
Bone Solutions closed a funding round for a total of >US $1.7MM, and affirmed an additional $1.65MM commitment from Next Health, its distribution partner.
Anika Therapeutics announced Canada launch of CINGAL® viscosupplement, cleared to treat knee osteoarthritis pain. CINGAL will be marketed by Pendopharm.
Johnson & Johnson is collaborating with a subsidiary of HP on use of 3D printing technologies to develop patient-customized products that can be manufactured quickly.